Pentaphenylcyclopentadienyl ruthenium complexes (3) are excellent catalysts for the racemization of secondary alcohols at ambient temperature. The combination of this process with enzymatic resolution of the alcohols results in a highly efficient synthesis of enantiomericallypure acetates at room temperature with short reaction times for most substrates. This new reaction was applied to a wide range
PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
申请人:Messersmith David
公开号:US20110081316A1
公开(公告)日:2011-04-07
The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Amino Alcohols in Organocatalysed Acylation and Deacylation: The Effect of Dialkylamino Substituents on the Rate
作者:Ludger A. Wessjohann、Mingzhao Zhu
DOI:10.1002/adsc.200600491
日期:2008.1.4
enhance the reactivity towards acylation and deacylation, respectively, that is, such amino alcohols can act as transacylation catalysts like DMAP. This effect is dependent on the number of (carbon) spacer atoms, flexibility of the molecule and the presence and position of further heteroatoms. Based on this effect, the site selective acylation and deacylation of desmycosin, a macrocycle antibiotic possessing
Cytochrome P450 Oxidase Inhibitors and Uses Thereof
申请人:Klein Larry L.
公开号:US20080161246A1
公开(公告)日:2008-07-03
The present invention features compounds of formula I
or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF
申请人:Klein Larry L.
公开号:US20120083490A1
公开(公告)日:2012-04-05
The present invention features compounds of formula I
or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.